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Abstract
Background Hospital-discharged patients with schizoaf-
fective disorder have a high risk of re-hospitalization.
However, limited data exist evaluating critical post-dis-
charge periods during which the risk of re-hospitalization is
significant.
Objective Among hospital-discharged patients with
schizoaffective disorder, we assessed pharmacotherapy
adherence and healthcare utilization and costs during
sequential 60-day clinical periods before schizoaffective
disorder-related hospitalization and post-hospital discharge.
Methods From the MarketScan Medicaid database
(2004–2008), we identified patients (C18 years) with a
schizoaffective disorder-related inpatient admission. Study
measures including medication adherence and healthcare
utilization and costs were assessed during sequential pre-
admission and post-discharge periods. We conducted uni-
variate and multivariable regression analyses to compare
schizoaffective disorder-related and all-cause healthcare
utilization and costs (in 2010 US dollars) between each
adjacent 60-day post-discharge periods. No adjustment was
made for multiplicity.
Results We identified 1,193 hospital-discharged patients
with a mean age of 41 years. The mean medication adher-
ence rate was 46 % during the 60-day period prior to index
inpatient admission, which improved to 80 % during the
60-day post-discharge period. Following hospital discharge,
schizoaffective disorder-related healthcare costs were sig-
nificantly greater during the initial 60-day period compared
with the 61- to 120-day post-discharge period (mean
US$2,370 vs US$1,765; p \ 0.001), with rehospitalization
(36 %) and pharmacy (40 %) accounting for over three-
fourths of the initial 60-day period costs. Compared with the
initial 60-day post-discharge period, both all-cause and
schizoaffective disorder-related costs declined during the
61- to 120-day post-discharge period and remained stable
for the remaining post-discharge periods (days 121–365).
Conclusions We observed considerably lower (46 %)
adherence during 60 days prior to the inpatient admission;
in comparison, adherence for the overall 6-month period
was 8 % (54 %) higher. Our study findings suggest that
both short-term (e.g., 60 days) and long-term (e.g.,
6–12 months) medication adherence likely are important
characteristics to examine among patients with schizoaf-
fective disorder and help provide a more holistic view of
patients’ adherence patterns. Furthermore, we observed a
high rate of rehospitalization and greater healthcare costs
during the initial 60-day period post-discharge among
patients with schizoaffective disorder. Further research is
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required to better understand and manage transitional care
after discharge (e.g., monitor adherence), which may help
reduce the likelihood of rehospitalization and the associ-
ated downstream costs.
Key Points for Decision Makers
Short-term (e.g., 60 days) adherence coupled with
long-term (e.g., 365 days) adherence to the
prescribed therapy provides a holistic view of
adherence patterns among the schizoaffective
disorder patient population.
This study identifies the critical post-discharge
period during which patients with schizoaffective
disorder have significantly greater likelihood of
rehospitalization and higher costs.
Decision makers should evaluate and consider the
allocation of additional resources for post-discharge
interventions (e.g., pharmacists/nurse counseling,
developing post-discharge follow-up plans) which
may help lower the cost and rehospitalization burden
during the critical post-discharge period.
The poor medication adherence and substantial
economic burden observed among patients with
schizoaffective disorder highlight the need for
conducting studies independently among patients
with schizoaffective disorder rather than as part of a
schizophrenia population.
1 Introduction
Schizoaffective disorder is a psychiatric disorder charac-
terized by depressive, manic, and psychotic symptoms. The
prevalence of schizoaffective disorder is estimated to be
approximately one-third to one-sixth as common as
schizophrenia (about 0.3 % in the United States) [1, 2]. Even
with lower prevalence than schizophrenia, findings from a
recent US hospital discharge survey suggest that a slightly
greater number of hospital-discharged patients had a schiz-
oaffective disorder diagnosis (primary) than had schizo-
phrenia [3]. In addition, persons with this diagnosis have
been suggested to have a greater risk of suicide, substance
abuse, and hepatic function abnormalities [4]. Patients with
schizoaffective disorder often experience hallucinations,
delusions which are characteristic of schizophrenia, as well
as mood symptoms such as mania and depression that are
associated with bipolar disorder. Literature suggests that age
of onset for adult schizoaffective disorder spans age of onset
of bipolar disorder and schizophrenia, with median age
falling between the median age of schizophrenia and bipolar
disorder [5]. Schizoaffective disorder is more common
among females whereas schizophrenia is more common
among males; an equal gender distribution is reported for
bipolar disorder [5–8]. Overall, the overlap of symptoms of
schizoaffective disorder with those of schizophrenia and
bipolar disorder makes the clinical diagnosis difficult [9, 10]
and the complex interplay of symptoms poses challenges to
treatment which are frequently managed by polypharmacy.
This increases the complexity of treatment with increased
potential problems of adherence, drug-drug interactions, and
cost of therapy.
As a chronic condition, schizoaffective disorder requires
long-term pharmacologic treatment that includes acute
treatment to manage symptom exacerbations, and mainte-
nance therapy to lower the risk of relapse. Pharmacologic
treatment generally includes antipsychotics used in com-
bination with mood stabilizers or antidepressants [1, 11–
14]. Given that pharmacological treatment plays a key role
in schizoaffective disorder management, it is important that
patients receive continuous effective coverage with them.
Patients with schizophrenia or schizoaffective disorder who
use medication irregularly are approximately twice as
likely to be rehospitalized and have 12 % higher inpatient
costs than patients who use their medication regularly [15].
Additionally, hospitalized patients with schizoaffective
disorder have an increased likelihood of relapse and
rehospitalization immediately following hospital discharge.
The risk is even greater than that for patients with
schizophrenia [16]. One study found that patients with
schizoaffective disorder are 1.8 times more likely to
experience a rehospitalization than patients with schizo-
phrenia [17]. Among patients with schizoaffective disorder,
increased risk of readmission following hospital discharge
may lead to higher healthcare costs. In this study we
examine healthcare utilization, and costs for patients with
schizoaffective disorder over small (60-day), sequential
periods during the high-risk post-discharge period.
2 Methods
2.1 Study Design and Data Source
This retrospective cohort study was conducted using
MarketScan’s Medicaid Multi-State (MMM) database from
2004 through 2008. This database contains information
contributed from 11 US states. For confidentiality pur-
poses, the states contributing data are not explicitly iden-
tified. The data include medical claims for services
provided at various care settings (e.g., inpatient, outpatient,
and emergency department [ER]) and outpatient pharmacy
claims. Medical claims include details on physician diag-
nosis, date of service, length of stay (inpatient services),
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procedures performed, and information on payments made
to a provider for services. Similarly, outpatient pharmacy
claims include details on the generic name of the pre-
scribed medication, national drug code, date of service,
days’ supply, and payment. In addition, the data also
include details on patient demographic characteristics (e.g.,
age, gender) and health plan enrollment details (e.g.,
enrollment period, plan type, mental health coverage). The
database employs a unique encrypted patient identifier that
enables patients to be tracked longitudinally.
2.1.1 Study Sample
Patients from the MMM database with an inpatient admis-
sion primary diagnosis of schizoaffective disorder (Inter-
national Classification of Diseases, 9th Revision, Clinical
Modification [ICD-9-CM] diagnosis code 295.7x) during
the period July 1, 2004 through December 31, 2007 were
identified for this analysis. The date for the first observed
inpatient admission was designated the ‘index admission
date,’ and the date of discharge associated with the index
admission was designated the ‘index discharge date.’
Patients were required to have a continuous Medicaid
enrollment for up to 6 months before the index admission
date (i.e., pre-index period), during the index hospitaliza-
tion episode, and up to 12 months after the index discharge
date (i.e., post-index period). Since the selection of patients
with schizoaffective disorder was based on ICD-9-CM
codes, any coding inaccuracies may lead to misclassifi-
cation of patients. Thus, additional inclusion and exclusion
criteria were applied to help improve the ascertainment of
patients with schizoaffective disorder. Patients were
required to have at least one schizoaffective disorder-rela-
ted outpatient or physician office visit or at least two pre-
scription claims for antipsychotics, antidepressants, or
mood stabilizers. This may have been present anytime
during the 6-month pre-index period or the 12-month post-
index period. Patients were excluded if they had a claim
with a diagnosis for other psychiatric conditions during the
post-index period. The exclusion criterion varied, depend-
ing on the psychiatric condition. Patients with at least one
primary diagnosis claim for bipolar disorder (ICD-9-CM
codes 296.0x, 296.1x, 296.4x-296.8x, 301.1) or schizo-
phrenia (ICD-9-CM code 295.xx [except 295.7x]) and
patients with two or more primary diagnosis claims for
unipolar disorder (ICD-9-CM codes 296.2x, 296.3x,
298.0x, 300.4, 311) during the 12-month post-index period
were excluded. This criterion was applied to minimize the
likelihood of misclassification of schizoaffective disorder
with other psychiatric conditions.
Furthermore, to ensure that the selected index inpatient
admission event was the first observed schizoaffective dis-
order-related inpatient admission and not a readmission, we
excluded patients with an inpatient admission with a schiz-
oaffective disorder diagnosis (primary or secondary) any
time during the 6-month pre-index period (i.e., clean period).
Patients were excluded if they were 18 years or younger at
their index admission date. To be able to fully capture
patients’ health service utilization and costs, we excluded
patients who were 65 years or older (i.e., Medicare-eligible
patients) at follow-up end date (i.e., index discharge date plus
360 days) and patients who were eligible for both Medicare
and Medicaid. Finally, patients without mental health and
substance abuse coverage were excluded from this study.
2.2 Study Measures
2.2.1 Medication Adherence
Adherence to schizoaffective disorder-related medications
(i.e., antipsychotics, antidepressants, and mood stabilizers)
was assessed using the proportion of days covered (PDC)
measure. PDC was calculated as:
PDC = total days of drug availability (days’ supply) in
the period of evaluation7 (number of days in the period of
evaluation – number of days hospitalized during the period
of evaluation)
When calculating the PDC, drug availability was
assessed for each day of the study period. Given the mul-
tiple time points of evaluation (the 60-day increments in
the pre-index and post-index periods), PDC was deemed
more appropriate in calculating adherence rate than mea-
suring the cumulative drug exposure as determined by the
commonly used measure ‘medication possession ratio’
[18–20]. PDC was calculated for all schizoaffective dis-
order-related medications received during the follow-up
period, irrespective of whether these medications were
received as monotherapy or as combination therapy.
Among patients receiving combination therapy (e.g., an
antipsychotic and a mood stabilizer), as long they had
evidence for one or more drugs on a day they were clas-
sified as being adherent for that day.
One of the limitations of inpatient claims data is that
details regarding inpatient medication use are not available.
To address this limitation, we assumed that patients were
fully compliant with their prescribed drug regimens during
an inpatient stay; we therefore subtracted hospitalization
days from the denominator [18, 21]. Furthermore, our data
did not include days’ supply details for injectable drugs
administered at a physician’s office. Thus, in calculating
PDC for depot antipsychotics administered at a physician’s
office, we used labeled dosage duration (i.e., risperidone
2 weeks, fluphenazine 3 weeks, and haloperidol 4 weeks)
as a proxy for days’ supply.
After calculating PDC, we categorized patients as
adherent if their PDC value was 0.8 or greater and
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nonadherent if their PDC value was \0.8 [22–25]. Medi-
cation adherence was assessed for each 60-day interval in
the pre- and post-index periods. We also assessed adher-
ence for the overall 6-month pre-index and post-index
periods and for the overall 12-month post-index period.
2.2.2 Healthcare Utilization and Costs
We assessed all-cause and schizoaffective disorder-related
healthcare utilization and costs on a short-term, sequential
basis for each 60-day interval in the 12-month post-index
period. In addition, we assessed all-cause and schizoaf-
fective disorder-related healthcare utilization and costs on a
long-term basis during the 6-month pre-index and post-
index periods and the overall 12-month post-index period.
Since costs incurred during the index inpatient admission
are neither part of the pre- nor the post-index period costs,
they were not considered in calculating the pre-index and
post-index period costs. Schizoaffective disorder-related
healthcare utilization was defined as medical claims with a
primary diagnosis code for schizoaffective disorder or
outpatient pharmacy claims for schizoaffective disorder-
related medications, including antipsychotics, antidepres-
sants, and mood stabilizers. Both all-cause and schizoaf-
fective disorder-related healthcare utilization and costs
were assessed and reported by care settings, including
inpatient, outpatient, physician office, ER, pharmacy, and
other ancillary care. All costs outcomes were adjusted to
2010 US dollars using the medical care component of the
Consumer Price Index.
Finally, for each patient, we calculated per-day costs for
an inpatient episode as:
Total costs for an inpatient episode 7 length of stay
For patients whose inpatient stay spanned two or more
follow-up periods (e.g., 0- to 60-day and 61- to 120-day
periods), we calculated length of stay for each period.
Further, the length of stay in each follow-up period was
multiplied by per-day cost to provide total inpatient costs
for each follow-up period.
2.3 Statistical Analysis
The key explanatory variables considered for this study
were indicators for the 60-day follow-up periods. All study
measures were compared between two contiguous 60-day
follow-up periods (e.g., 0–60 and 61–120 days), with the
former period being the reference group (e.g., 0–60 days).
Since we wanted to assess if healthcare utilization and costs
varied (increases or decreases) over time we considered
contiguous 60-day follow-up periods for comparisons rather
than anchoring the comparisons to a single period (e.g.,
0–60 days). Other covariates considered were age at the
index admission date, gender, race, plan type, basis of
Medicaid eligibility, index hospitalization discharge status,
and baseline comorbidity burden (assessed using the
Charlson Comorbidity Index score) [26]. The data did not
include information on disease severity. Prior studies con-
ducted among patients with mental health disorders have
used prior costs as a proxy measure for disease severity and
predictor of future healthcare costs [27–29]. Therefore, we
used pre-index costs, calculated as the sum of all healthcare
costs incurred during the 6-month pre-index period as a
covariate in the regression analyses. Patients were catego-
rized as ‘high-cost users’ (pre-index period costs C75th
quartile) and ‘non-high-cost users’ (i.e., pre-index period
costs \75th quartile) based on the pre-index period costs.
The 75th quartile costs cut-off used was US$15,650.
Descriptive statistics, including means and standard
deviations (SDs), were reported for continuous variables,
while counts and percentages were reported for categorical
variables. For unadjusted analyses, we used paired t tests
(i.e., continuous measures) and McNemar’s test (i.e., cat-
egorical measures) to compare the outcome measures
between each adjacent study period.
Healthcare utilization and costs were also compared
between each contiguous follow-up period, using covari-
ate-adjusted (i.e., baseline demographic and clinical char-
acteristics) regression models. Count data outcomes (e.g.,
number of unique hospitalizations) were compared using
repeated-measure Poisson or negative binomial regression
models. For each count data outcome, selection of a
Poisson or negative binomial regression model was made
by model fit, which was determined by the Pearson chi-
square test. The incident rate ratio (IRR) generated using
the Poisson or negative binomial regression model repre-
sents the increased or decreased rate of healthcare utiliza-
tion during a follow-up period relative to the reference
follow-up period. Finally, healthcare costs were compared
using repeated-measure generalized linear models with a
log-link function and gamma distribution. A generalized
linear model was chosen over a log-transformed ordinary
linear regression because it estimates covariate-adjusted
predicted mean costs on a dollar scale and thus avoids
potential biases resulting from the Duan smearing method
for retransforming [30–32]. In our study sample, only a
small number of patients (\1.5 %) experienced an ER
event during the follow-up; thus, we could not conduct
covariate-adjusted regression analyses to compare ER uti-
lization and costs between each continuous follow-up
period. No adjustment was made for multiplicity.
3 Results
After applying the study’s inclusion and exclusion criteria,
1,193 patients were included in our final sample (Online
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Resource 1 includes a figure depicting the study periods
[Supplementary Figure 1] and an attrition chart [Supple-
mentary Figure 2] which documents how this sample was
identified). Baseline patient characteristics are shown in
Table 1. The mean age of these patients was 41 years,
61 % were female, and 48 % were white. Sixty-eight
percent of these patients had fee-for-service coverage and
92 % were ‘discharged to home for self-care’ following an
inpatient admission. Approximately 25 % of patients had
high healthcare costs (high costs cut-off used was
US$15,650) in the 6-month pre-index period.
3.1 Medication Adherence
Table 2 summarizes adherence to schizoaffective disorder-
related medications in the 6-month pre-index and the
12-month post-index periods. During the pre-index period,
medication adherence rates as measured by PDC declined
from 0.65 (SD 0.38) in the 182- to 121-day period to 0.46
(SD 0.45) in the 60- to 0-day period. Compared with the
initial 60-day pre-index period, a higher adherence rate was
observed in the initial 60-day post-index period (PDC 0.80;
SD 0.27). However, the adherence rate dropped to 0.63 (SD
0.40) in the 61- to 120-day post-index period and remained
relatively stable in the 121- to 180-day post-index periods
(PDC 0.62; SD 0.42). When looking at the longer term
adherence, on average, the PDC measured during the
6-month post-index period was higher than the overall PDC
measured during the 6-month pre-index period (0.69 vs
0.54). Similarly, we observed a higher percentage of
patients who adhered to their treatment during the 6-month
post-index period than during the 6-month pre-index period
(51 vs 37 %).
3.2 Unadjusted Healthcare Utilization and Costs
We observed greater schizoaffective disorder-related and
all-cause healthcare utilization and costs during the initial
0- to 60-day post-discharge period compared with other
follow-up periods (Fig. 1). Thus, the results presented here
primarily focus on comparing healthcare utilization for the
two initial post-discharge periods (i.e., 0- to 60-day and 61-
to 120-day periods) (Figs. 2, 3). However, data for all study
periods are presented in tabular format (Online Resource
1—Supplementary Tables 1 and 2).
3.2.1 Unadjusted Schizoaffective Disorder-Related
Utilization and Costs
We observed a greater percentage of patients with at least
one schizoaffective disorder-related encounter in the initial
0- to 60-day post-index period than in the 61- to 120-day
post-index period (82 vs 72 %; p \ 0.001). A significantly
Table 1 Patient characteristics
N (mean) % (SD)




Age (years) at index admission datea















Basis of medicaid eligibility
Blind/disabled individual 1,085 90.95
Adult (not based on unemployed
status)
80 6.71
Child (not child of unemployed




Discharged to home self-care 1,097 91.95
Transfer to SNF 13 1.09
Transfer to other facility 39 3.27
Left against medical advice 8 0.67
Other alive status 1 0.08
Not yet discharged/transferred 10 0.84
Missing/unknown 25 2.10
Pre-index periodc all-cause healthcare costs (USD)
Mean (SD) US$11,577.20 (US$13,324.09)
High-cost users
Non-high cost (i.e., pre-index
period costs \75th quartile)
899 75.36
High cost (i.e., pre-index period
costs C75th quartile)
294 24.64
Pre-index Period Charlson Comorbidity Index Score
Mean (SD) 1.09 (1.71)
SD standard deviation, SNF skilled nursing facility
a The date for the first observed schizoaffective disorder-related
inpatient admission will define the index admission date
b ‘Other’ includes foster-care child, aged individual, and eligibility
status unknown
c The 6-month period before the index admission date defines the
pre-index period
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greater proportion of patients had at least one schizoaf-
fective disorder-related prescription filled during the initial
60-day post-index period than in the 61- to 120-day post-
index period (90 vs 78 %; p \ 0.001). Other care settings
with significantly greater schizoaffective disorder-related
utilization during the initial 60-day period than in the 61- to
120-day period included inpatient services (p \ 0.001),
office visits (p = 0.02), and other ancillary care
(p \ 0.001). Schizoaffective disorder-related healthcare
utilization declined and remained stable after the initial
60-day post-index period.
Schizoaffective disorder-related healthcare costs (mean
US$2,370 vs US$1,765; p \ 0.001) were significantly
greater in the initial 0- to 60-day post-index period than in
the adjacent 61- to 120-day post-index period. The primary
drivers of schizoaffective disorder-related costs in the 0- to
60-day post-index period were rehospitalization (mean
US$860; SD US$3,923) and pharmacy (mean US$954; SD
US$926). Schizoaffective disorder-related costs declined
and remained stable after the initial 60-day post-index
period (range of means US$1,523–US$1,764). No signifi-
cant differences in schizoaffective disorder-related costs
were observed in care settings including outpatient, phy-
sician office, and inpatient for the remaining post-index
periods (all p values [0.05).
Finally, we observed significantly greater schizoaffec-
tive disorder-related mean total medical costs during the
6-month post-index discharge period compared with the
6-month pre-index period (US$5,658 vs US$2,925;
p \ 0.001).
3.2.2 Unadjusted All-Cause Utilization and Costs
A significantly greater percentage of patients had an all-
cause hospitalization (15.9 vs 10.1 %; p \ 0.001) and
greater mean [SD] hospitalization costs (US$1,521
[US$5,912] vs US$961 [US$3,869]; p \ 0.001) during the
initial 0- to 60-day post-discharge period compared with
the 61- to 120-day post-discharge period. We also observed
greater all-cause costs in pharmacy (US$1,567 [US$1,314]
vs US$1,327 [US$1,267]; p \ 0.001) and hospital outpa-
tient (US$240 [US$1,360] vs US$167 [US$734];
p = 0.016) care settings during the 0- to 60-day post-index
discharge period compared with the 61- to 120-day post-
discharge period. Following the initial 0- to 60-day post-
discharge period, all-cause total medical costs (US$5,277
[US$7,649]) declined during the 61- to 120-day post-dis-
charge period (US$4,310 [US$6,033], p \ 0.001) and
remained stable during the remaining 60-day post-index
discharge periods (range of means US$3,998–US$4,601).
Table 2 Adherencea to schizoaffective disorder-related medicationsb
Adherence Pre-index periodc
182–121 days 121–61 days 60–0 days Overall 6 months
PDCe
Mean (SD) 0.65 (0.38) 0.49 (0.44) 0.46 (0.45) 0.54 (0.37)
PDC categorical (80 % threshold), n (%)
Nonadherent total (PDC \80 %) 569 (47.69) 715 (59.93) 737 (61.78) 756 (63.37)
Adherent total (PDC C80 %) 624 (52.31) 478 (40.07) 456 (38.22) 437 (36.63)
Total 1,193 (100.00) 1,193 (100.00) 1,193 (100.00) 1,193 (100.00)
Adherence Post-index periodd
0–60 days 61–120 days 121–180 days Overall 6 months
PDCe
Mean (SD) 0.80 (0.27) 0.63 (0.40) 0.62 (0.42) 0.69 (0.32)
PDC categorical (80 % threshold), n (%)
Nonadherent total (PDC \80 %) 410 (34.37) 552 (46.27) 562 (47.11) 579 (48.53)
Adherent total (PDC C80 %) 783 (65.63) 641 (53.73) 631 (52.89) 614 (51.47)
Total 1,193 (100.00) 1,193 (100.00) 1,193 (100.00) 1,193 (100.00)
PDC proportion of days covered, SD standard deviation
a Adherence was measured during the 6-month post-index date
b Includes antipsychotics, antidepressants, and mood stabilizers
c 6-month period before the index admission date
d 6-month period following the index discharge date
e PDC = total days of drug availability 7 (days in study period - days hospitalized)
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Finally, all-cause total medical costs were significantly
greater during the 6-month post-discharge date period
compared with the 6-month pre-index period (US$13,732
[US$16,953] vs US$11,462 [US$13,132]; p \ 0.001).
3.3 Covariate-Adjusted Healthcare Utilization
and Costs
Figure 2 presents risk-adjusted IRRs for all-cause and
schizoaffective disorder-related healthcare utilization, by
care settings, for the 0- to 60-day and the 61- to 120-day
post-index discharge periods. Similarly, Fig. 3 presents
covariate-adjusted predicted all-cause and schizoaffective
disorder-related healthcare costs, by individual care set-
tings, for the 0- to 60-day and the 61- to 120-day post-index
discharge periods. Risk-adjusted IRRs for all-cause and
schizoaffective disorder-related healthcare utilization, by
care settings, for the remaining follow-up periods are
presented in Online Resource 1—Supplementary Table 3.
Finally, the Online Resource 1—Supplementary Table 4
presents detailed regression model results for two outcome
measures including schizoaffective disorder-related pre-
scription drug costs and schizoaffective disorder-related
prescription drug count.
3.3.1 Covariate-Adjusted Schizoaffective
Disorder-Related Utilization and Costs
Consistent with the unadjusted results, the adjusted results
illustrate that the rates of service use for schizoaffective
disorder-related pharmacy (IRR 0.81; confidence interval
[CI] 0.77–0.85; p \ 0.001), outpatient (IRR 0.61; 95 % CI
0.40–0.93; p = 0.022) and inpatient (IRR 0.53; 95 % CI
0.41–0.69; p \ 0.001) services use were significantly lower
in the 61- to 120-day post-index period than in the initial
60-day post-index period. However, we did not observe
significant differences in schizoaffective disorder-related
inpatient utilization rate for the remaining post-index dis-
charge periods relative to its immediate predecessor period:
121–180 days (IRR 0.79; p = 0.149; compared with
61–120 days), 181–240 days (IRR 0.96; p = 0.871; com-
pared with 121–180 days), 241–300 days (IRR 1.05;
p = 0.767; compared with 181–240 days) and 301–364 days
A All Cause Costs
B  Schizoaffective Disorder-related Costs
Fig. 1 Overall follow-up period unadjusted all-cause and schizoaf-
fective disorder-related healthcare costs by care setting (the 12-month
period following the index discharge date defines the post-index
period)
A  All-cause Utilization
B   Schizoaffective Disorder-related Utilization
Fig. 2 Follow-up period (0–60 days vs 61–120 days) risk-adjusted
incident rate ratios for all-cause and schizoaffective disorder-related
health care utilization, by care setting (incident rate ratios based on
negative binomial or Poisson regression models, adjusted for study
period and other relevant covariates [i.e., gender, race, age, Charlson
Comorbidity Index score, healthcare plan type, discharge status,
antipsychotic adherence, and pre-index period healthcare cost]).
Graph presents incident rate ratios and corresponding 95 % confi-
dence intervals comparing care setting-specific utilization rates during
the 61–120 and 0–60 day (reference group) post-discharge periods
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(IRR 1.07; p = 0.694; compared with 241–300 days)
(Online Resource 1—Supplementary Table 3). Schizoaf-
fective disorder-related costs were lower across care set-
tings, including pharmacy, physician office, hospital
outpatient, and inpatient care, during the 61- to 120-day
post-index discharge period compared with the 0- to
60-day post-index discharge period (Fig. 3).
3.3.2 Covariate-Adjusted All-Cause Utilization and Costs
The utilization rate was 16 % lower for all-cause pharmacy
services (IRR 0.84; 95 % CI 0.81–0.87; p \ 0.001) and
38 % lower for all-cause inpatient admissions (IRR 0.62;
95 % CI 0.51–0.76; p \ 0.001) in the 61- to 120-day post-
index period compared with the 0- to 60-day post-index
period. However, all-cause inpatient utilization rates did
not differ for the remaining post-index discharge periods:
121–180 days (IRR 0.70; p = 0.338; compared with
61–120 days), 181–240 days (IRR 0.89; p = 0.351;
compared with 121–180 days), 241–300 days (IRR 1.18;
p = 0.163; compared with 181–240 days) and
301–364 days (IRR 1.09; p = 0.430; compared with
241–300 days). After adjusting for covariates, the pre-
dicted all-cause costs were significantly lower for various
care settings, including pharmacy (US$1,448 vs US$1,673;
p \ 0.001), hospital outpatient (US$576 vs US$708;
p \ 0.001), and inpatient (US$7,585 vs US$9,200;
p \ 0.001) costs during the 61- to 120-day post-index
discharge period than during the 0- to 60-day post-index
discharge period.
4 Discussion
Our study documents medication adherence patterns,
healthcare utilization, and healthcare costs at sequential,
clinically relevant, 60-day periods before an inpatient
admission and post-hospital discharge among Medicaid-
enrolled patients with schizoaffective disorder. Adherence
to prescribed medications declined during each of the
60-day pre-index periods with the lowest rate observed
during the 60-day period immediately prior to the inpatient
admission. In contrast, adherence to schizoaffective disor-
der-related medications was highest during the 60-day
period immediately following hospital discharge. Simi-
larly, schizoaffective disorder-related costs and utilization
were significantly higher during the initial 0- to 60-day
post-discharge period compared with the 61- to 120-day
post-discharge period.
Previous studies have suggested low adherence is
associated with an increased risk of relapse and rehospi-
talization among patients with schizophrenia and schizo-
affective disorder [15, 16, 33]. Typically, administrative
claims-based studies assessing therapy adherence among
patients with psychiatric conditions have focused on mea-
suring long-term (e.g., 365 days) adherence [34–36]. In
general, long-term adherence is an important measure of
patient behavior towards the prescribed therapy and lower
adherence rates (\80 %) have been shown to be associated
with higher healthcare utilization and costs [37–39].
An important limitation of long-term adherence assess-
ment using measures such as medication possession ratio
(MPR) is that the entire adherence assessment period is
equivalently weighted. Limiting the assessment of adher-
ence to long periods without understanding the details
around smaller intervals during which a patient may be
non-adherent to the prescribed therapy reduces our ability
to interpret the data. Two scenarios may help to clarify.
Scenario 1: Patient A refills a 30-day supply of antipsy-
chotic medication ten times in 1 year and with a 7-day gap
between each refill, resulting in an annual adherence rate of
82 % (300 days of drug on hand/365 days); Scenario 2:
A   All Cause Costs
B   Schizoaffective Disorder-related Costs
Fig. 3 Follow-up period risk-adjusted all-cause and schizoaffective
disorder-related healthcare costs (predicted costs estimates and
corresponding 95 % confidence intervals based on generalized linear
models, and corresponding p values based on paired t tests), by care
setting. p \ 0.001
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Patient B refills a 30-day supply of antipsychotic medica-
tion ten times in 1 year and with a 65-day gap after the last
refill, also resulting in an annual adherence rate of 82 %
(300 days of drug on hand/365 days). Although both
patients have the same number of days without drug
annually, Patient A’s poor adherence is distributed
throughout the 12-month period, whereas that for Patient B
is concentrated after the last prescription refill. Patient B
with the concentrated gap is potentially at greater risk of
having a relapse than Patient A. Thus, further studies
evaluating the impact of concentrated and dispersed gaps in
prescribed therapy and relapse rate are required. In this
study we present both long- (6 months) and short-term
(60-day period) adherence. The mean PDC for 6 months
prior to inpatient admission was 54 % whereas mean PDC
during the 60-day period to the inpatient admission was
46 %. Thus, a more detailed analysis of adherence
including short- and long-term timeframes should help
understand patients’ adherence behavior rather than only
using short- or long-term adherence measures. Further-
more, short-term adherence may also help better identify
patients at risk for relapse and needs to be studied further.
Among the selected patients, adherence to schizoaffec-
tive disorder-related pharmacotherapy generally declined
over time during the period prior to the index inpatient
admission. Patients with schizoaffective disorder are often
managed by a combination of antipsychotics, antidepres-
sants, and mood stabilizers, and patients using multiple
medications within these classes may require regular blood
level testing. The complexity and burden of the treatment
in persons whose symptoms are associated with cognitive
difficulties and apathy may lead to treatment overload and
neglect of the treatment plan provided by their physician.
The consequent loss of adequate exposure to therapy is
likely to lead to relapse and hospitalization.
Another important finding of this study was the identi-
fication of the period of greatest risk for rehospitalization in
these patients as the 60 days immediately following dis-
charge. In addition, the total schizoaffective disorder-
related costs during this 60-day interval were more than
30 % greater than the costs in any of the subsequent 60-day
post-discharge periods.
The increased risk of rehospitalization observed during
this interval may be related to incomplete stabilization
while hospitalized and to inadequate timely follow up
immediately after discharge [16, 17, 40–42]. Several
studies have found that failure to achieve such timely fol-
low-up care is linked to an increased risk of rehospitali-
zation [43, 44]. In this study, only 15 % of patients had a
schizoaffective disorder-related follow-up physician office
visit during the 60-day post-discharge period. This suggests
that one way to reduce high post-index costs and reduce the
risk of readmission is to improve patients’ transition from
an inpatient setting to an outpatient setting. It has been
reported that better continuity of care among patients with
severe mental illness was associated with reduced hospital
costs, improved quality of life and functioning, and
reduced severity of symptoms [45, 46]. Thus, tailored
management and treatment strategies during the first
60 days after hospitalization may be of particular impor-
tance. Supporting this concept, the proposed Healthcare
Effectiveness Data and Information Set (HEDIS) health
plan has set assessment of the rate of 7- and 30-day post-
discharge follow-up outpatient visits as a performance
measure for patients with schizophrenia or schizoaffective
disorder [47, 48].
Overall, this study has several unique attributes. First,
this study used a multi-state (11 states) Medicaid database
and thus helped understand adherence patterns and
resource utilization patterns across a geographically
diverse population of Medicaid enrollees diagnosed with
schizoaffective disorder. Furthermore, Medicaid is the
largest payer for mental health care and facing declining
funding and thus, measures to identify high risk and high
utilizers of mental health services are necessary [49–52].
Secondly, our study applied several criteria to ensure that
coding for schizoaffective disorder was captured as accu-
rately as possible. Thirdly, our study findings indicate that
the measures assessed in our study including short-term
and long-term adherence and utilization over smaller
sequential periods can serve as useful tools to identify
high-risk patients who can be targeted for interventions to
lower the readmission risk and the associated downstream
costs. Moreover, these measures can be applied to other
mental health conditions (e.g., schizophrenia, bipolar dis-
order) and using the low-cost administrative claims data,
which are generated and provided by the Centers for
Medicare and Medicaid on an annual basis.
However, several limitations should be considered in
interpreting the study findings. First, the study was con-
ducted using Medicaid claims data. Although there are not
obvious differences in the patients in this set compared
with others, it remains to be seen if these findings will
generalize to uninsured populations or to individuals cov-
ered under commercial or public plans (e.g., Medicare). In
addition, we excluded patients with dual eligibility (i.e.,
Medicare and Medicaid) and patients 65 years or older
since these patients are primarily covered by Medicare, and
Medicaid claims data may not fully capture health service
utilization and costs for these patients. Thus, the study
findings cannot be extrapolated to elderly patients with
schizoaffective disorder. Furthermore, the inclusion and
exclusion criteria used to select the study cohort may limit
the generalizability of the results. For example, in order to
ensure that each selected patient has a uniform length of
follow-up data, we required patients to have continuous
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Medicaid enrollment during the study period. Thus, the
selected study population excluded more severely ill
patients treated in long-term settings. Additionally, our
adherence measure was based on pharmacy claims, not on
actual medication consumption. A key assumption when
using this adherence measure is that the prescriptions that
were filled were consumed as scheduled. This is not likely
fully accurate in real world practice. Nevertheless, PDC
remains a validated proxy for true adherence and represents
one of the most commonly used approaches [18–20].
Furthermore, we assessed adherence to overall schizoaf-
fective disorder-related therapy and not individual drugs
among patients receiving two or more drugs simulta-
neously. Thus, among patients receiving combination
therapy (e.g., an antipsychotic and a mood stabilizer), as
long they had evidence for one or more drugs on a day they
were classified as being adherent for that day. This was
based on the assumption that patients are using some drug
to manage the condition. The limitation of this approach is
that among patients required to take multiple medications,
adherence may be overstated if all drugs in the combination
are necessary every day to confer a therapeutic benefit.
We assessed patient’s age at index admission date and
considered the commonly used age cut-off (i.e., C18 years)
to define adults in studies conducted using Medicaid dat-
abases including the MarketScan Multi-State database [53–
56]. The 17 patients with basis of eligibility as ‘Child (not
child of unemployed adult, not foster-care child)’that was
assessed at the index admission date can possibly be from
Medicaid states that consider 21 years as the age cut-off to
define adults. However, we do not have information on the
states contributing to the database and thus the age cut-off
used by these states to define adults and children could not
be determined. In addition, because patients’ out-of-pocket
costs and indirect costs, such as productivity losses and
caregiver costs, were not available in the dataset used for
these analyses, only direct medical costs paid by Medicaid
were assessed in this study. All costs measures reported in
this study are based on US$ 2010, which was the most
current complete year for which medical care component
of the US Consumer Price Index was available at the time
that this study was conducted. Finally, we were unable to
control for several factors that may affect adherence,
healthcare utilization, and costs (e.g., educational level and
medication-related adverse events), as this information was
unavailable in our data.
5 Conclusions
Overall, the lack of reliable diagnostic criteria often makes
diagnosis of schizoaffective disorder a challenge which
may explain the limited number of studies on
schizoaffective disorder. A recent study reports that in the
last 2 decades over 5,300 studies related to psychiatric
conditions (bipolar disorder, schizophrenia, schizoaffective
disorder) were published, of which *1 % related to
schizoaffective disorder [57]. Our study findings indicate
that a considerable number of Medicaid enrollees had a
schizoaffective disorder-related inpatient admission during
the study period. Thus, understanding medication adher-
ence and resource utilization independently among patients
with schizoaffective disorder is important. In contrast,
several previously published administrative claims-based
studies have not considered these patients independent
from the ones diagnosed with schizophrenia and have often
included patients diagnosed with schizoaffective disorder
as part of a schizophrenia cohort [58–62]. Our study helps
address this limitation by evaluating medication adherence
and resource utilization patterns across 60-day periods
before and after hospitalization specifically among patients
with schizoaffective disorder. We observed greater inpa-
tient and pharmacy utilization in the initial 60-day post-
discharge period than in any other 60-day intervals fol-
lowing discharge. Overall, findings from this study may
help identify high-risk, high-cost patients and aid in
designing interventions that may reduce the likelihood of
hospital admissions and reduce costs associated with the
care of schizoaffective patients.
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